BioCentury
ARTICLE | Clinical News

APX005M: Phase I started

August 10, 2015 7:00 AM UTC

Apexigen began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV APX005M every 3 weeks in about 32 patients. ...